Clinical Trials Logo
  1. Home
  2. Chikungunya Virus Infection
  3. NCT06028841

A Clinical Phase 3 Study of VLA1553 in Adult Participants With Human Immunodeficiency Virus (HIV)

Chikungunya Virus Infection Clinical Trial

Official title:
An Open-label Phase 3 Study to Assess the Safety and Immunogenicity of a Live-attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Moderately Immunocompromised Adult Participants Infected With Human Immunodeficiency Virus

Clinical Trial Summary

This is a phase 3 clinical study to evaluate the safety, tolerability, and immunogenicity of VLA1553 in moderately immunocompromised adults with HIV infection.

Clinical Trial Description

This is a multicenter, prospective, open-label, uncontrolled, single arm, phase 3 clinical study evaluating the final dose of VLA1553. The safety, tolerability, and immunogenicity of VLA1553 will be assessed in moderately immunocompromised adult participants infected with HIV living in CHIKV endemic areas. Approximately 75 male and female adults (aged 18 years or above) infected with HIV will be enrolled. Participants will be screened by ELISA for evidence of previous CHIKV exposure excluding CHIKV seropositive participants from study participation. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06028841
Study type Interventional
Source Valneva Austria GmbH
Contact Valneva Clinical Development
Phone +43 1 206 20
Email office@valneva.com
Status Recruiting
Phase Phase 3
Start date April 10, 2024
Completion date September 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02230163 - Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins Phase 1/Phase 2
Completed NCT04546724 - Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults Phase 3
Terminated NCT04455919 - Yoga for Chronic Chikungunya N/A
Completed NCT03631719 - Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
Active, not recruiting NCT04441905 - Phase 1 Study of SAR440894 vs Placebo Phase 1
Completed NCT02562482 - Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults Phase 2
Completed NCT03028441 - Phase I Trial of Measles Vectored Chikungungya Vaccine Phase 1
Completed NCT03807843 - Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006) Phase 2
Completed NCT04909411 - Consequences of a Maternal-fetal Chikungunya Virus Infection N/A
Completed NCT04786444 - Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults Phase 3
Completed NCT02553369 - Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection N/A
Recruiting NCT06106581 - A Phase 2 Clinical Study of VLA1553 in Healthy Children Aged 1 to 11 Years Phase 2
Recruiting NCT06007183 - Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination Phase 3
Completed NCT03635086 - Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005) Phase 2
Completed NCT02861586 - Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine Phase 2
Active, not recruiting NCT04838444 - Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553) Phase 3
Completed NCT03483961 - Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults Phase 2